How to buy Axonics stock

Axonics, Inc is a medical devices business based in the US. Axonics shares (AXNX) are listed on the NASDAQ and all prices are listed in US Dollars. Axonics employs 416 staff and has a trailing 12-month revenue of around 0.00.

Axonics share price

Use our graph to track the performance of AXNX stocks over time.

Axonics shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$30.00 - $64.36
50-day moving average	$59.06
200-day moving average	$52.06
Wall St. target price	$67.89
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.53

Buy Axonics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Axonics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Axonics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Axonics financials

Revenue TTM	$111.5 million
Gross profit TTM	$67.1 million
Return on assets TTM	-11.96%
Return on equity TTM	-23.35%
Profit margin	-49.24%
Book value	$7.20
Market capitalisation	$2.6 billion

TTM: trailing 12 months

Shorting Axonics shares

There are currently 4.2 million Axonics shares held short by investors – that's known as Axonics's "short interest". This figure is 2.3% down from 4.3 million last month.

There are a few different ways that this level of interest in shorting Axonics shares can be evaluated.

Axonics's "short interest ratio" (SIR)

Axonics's "short interest ratio" (SIR) is the quantity of Axonics shares currently shorted divided by the average quantity of Axonics shares traded daily (recently around 477805.33484677). Axonics's SIR currently stands at 8.81. In other words for every 100,000 Axonics shares traded daily on the market, roughly 8810 shares are currently held short.

However Axonics's short interest can also be evaluated against the total number of Axonics shares, or, against the total number of tradable Axonics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Axonics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Axonics shares in existence, roughly 100 shares are currently held short) or 0.1266% of the tradable shares (for every 100,000 tradable Axonics shares, roughly 127 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Axonics.

Find out more about how you can short Axonics stock.

Axonics share dividends

We're not expecting Axonics to pay a dividend over the next 12 months.

Axonics share price volatility

Over the last 12 months, Axonics's shares have ranged in value from as little as $30 up to $64.36. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axonics's is 0.0528. This would suggest that Axonics's shares are less volatile than average (for this exchange).

Axonics overview

Axonics, Inc. , a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc.

Frequently asked questions

• What percentage of Axonics is owned by insiders or institutions?

  Currently 5.99% of Axonics shares are held by insiders and 110.395% by institutions.

• How many people work for Axonics?

  Latest data suggests 416 work at Axonics.

• When does the fiscal year end for Axonics?

  Axonics's fiscal year ends in December.

• Where is Axonics based?

  Axonics's address is: 26 Technology Drive, Irvine, CA, United States, 92618

• What is Axonics's ISIN number?

  Axonics's international securities identification number is: US05465P1012

• What is Axonics's CUSIP number?

  Axonics's Committee on Uniform Securities Identification Procedures number is: 05465P101